跳至主要内容
临床试验/DRKS00025509
DRKS00025509已完成不适用

ung Artificial Intelligence-enabled Digital Solution Pilot Study - Lung AID Pilot Study

MSD SHARP & DOHME GmbH0 个研究点目标入组 47 人开始时间: 2021年9月21日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
47

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • 1. =18 years old at study inclusion
  • 2. Confirmed metastatic NSCLC as determined by the treating physician
  • 3. Previously untreated for metastatic disease with treatment decision already made by treating physician on first line therapy with pembrolizumab based regimen for metastatic disease as defined by European market authorization
  • 4. ECOG performance Status 0-2
  • 5. Owner of a web-connected, frequently used, electronic device (smartphone, tablet, computer) and an email address,
  • 6. Internet access available at home
  • 7. Fluent in written and spoken German
  • 8. Provided written informed consent for the study.

排除标准

  • 1. Patients previously documented within this study
  • 2. Has received systemic therapy for the treatment of their stage IV NSCLC at the time of enrollment
  • 3. Unable to participate in an initial training or to regularly use the Kaiku® Health AI-enabled remote symptom monitoring solution or the ePRO module as assessed by the treating physician during informed consent process

研究者

相似试验